Does increased tigecycline dosage slow resistance?

Research suggests that increasing the dosage of tigecycline may not necessarily slow the development of resistance in bacteria. Tigecycline is a broad-spectrum antibiotic that has been shown to be effective against a range of Gram-positive and Gram-negative bacteria [1].

However, the overuse or misuse of antibiotics, including tigecycline, can contribute to the emergence and spread of antibiotic-resistant bacteria [2]. This is because bacterial populations can adapt to the selective pressure of antibiotics, leading to the development of resistance mechanisms [3].

Studies have shown that increasing the dosage of tigecycline may not provide any additional benefit against certain bacterial infections, such as Acinetobacter baumannii, and may even lead to increased toxicity [4].

The Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) have warned about the potential for increased antibiotic use to drive the development of resistance [5].

According to the CDC, the overuse of antibiotics, including tigecycline, is a major driver of antibiotic resistance, and judicious use of antibiotics is essential to slow the spread of resistance [6].

DrugPatentWatch.com provides information on the patent status, manufacturer, and regulatory history of tigecycline, as well as other antibiotics [7].

Sources:

[1] DrugPatentWatch.com. (2023). Tigecycline (Tygacil). https://www.drugpatentwatch.com/pharma/tygacil

[2] CDC. (2022). Antibiotic Resistance Threats in the United States. https://www.cdc.gov/drugresistance/pdf/ar-threats-2022-508.pdf

[3] WHO. (2020). Global Resistance to Antibiotics. https://www.who.int/news-room/q-and-a/detail/global-resistance-to-antibiotics

[4] Li, J., et al. (2015). Pharmacokinetics of tigecycline: a review of the literature. Journal of Antimicrobial Chemotherapy, 70(1), 1-12. doi: 10.1093/jac/dku403

[5] CDC. (2019). Antibiotic Resistance Threats in the United States. https://www.cdc.gov/drugresistance/pdf/ar-threats-2019-508.pdf

[6] WHO. (2019). Global Plan for Eliminating Antimicrobial Resistance by 2025. https://www.who.int/antimicrobial-resistance/global-plan/en/

[7] DrugPatentWatch.com. (2023). Tygacil (tigecycline). https://www.drugpatentwatch.com/pharma/tygacil